The Senate Finance Committee unveiled a long-awaited drug-pricing bill, to be marked up Thursday (July 25), that includes monumental changes to drug-pricing policy in Medicare and Medicaid -- including restructuring the Part D benefit, imposing controversial inflationary rebates in Medicare Parts B and D, and raising the rebate cap in Medicaid. The Congressional Budget Office estimated that the package would save taxpayers $85 billion in Medicare and $15 billion in Medicaid; and beneficiaries $27 billion in out-of-pocket costs and $5...